Barclays initiated coverage on Owens & Minor with a new price target
$OMI
Medical Specialities
Health Care
Barclays initiated coverage of Owens & Minor with a rating of Equal Weight and set a new price target of $21.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/19/2024 | $24.00 → $19.00 | Neutral → Buy | Citigroup |
| 2/26/2024 | $24.00 | Market Perform | Leerink Partners |
| 1/3/2024 | $21.00 | Equal Weight | Barclays |
| 10/13/2022 | $52.00 → $18.00 | Buy → Neutral | Citigroup |
| 10/12/2022 | $43.00 → $17.00 | Buy → Underperform | BofA Securities |
| 10/12/2022 | $62.00 → $22.00 | Outperform → Neutral | Robert W. Baird |
| 4/26/2022 | $55.00 | Buy | Citigroup |
| 4/1/2022 | $43.00 | Neutral | Credit Suisse |
8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)
10-Q - OWENS & MINOR INC/VA/ (0000075252) (Filer)
8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
Citigroup upgraded Owens & Minor from Neutral to Buy and set a new price target of $19.00 from $24.00 previously
Leerink Partners initiated coverage of Owens & Minor with a rating of Market Perform and set a new price target of $24.00
Barclays initiated coverage of Owens & Minor with a rating of Equal Weight and set a new price target of $21.00
Gomez assumes leadership of Owens & Minor's people strategy with a focus on cultivating talent that supports company performance Owens & Minor, Inc. (NYSE:OMI), a leading global healthcare solutions company, today announced the appointment of Tammy Gomez as Executive Vice President & Chief Human Resources Officer, effective July 11, 2022. Gomez will report to Owens & Minor's President and Chief Executive Officer, Edward A. Pesicka, and be a member of the company's executive leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622005306/en/Owens & Minor names Tammy Gomez EVP and Chief Human Resources Officer, effect
Top-Line Growth Led by the Patient Direct Segment Patient Direct Operating Margin Expanded by 173 Basis Points Company Reaffirmed 2025 Financial Guidance Remain Actively Engaged in Potential Sale of Products & Healthcare Services Segment Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the first quarter ended March 31, 2025. "Across the business we continued to see strong execution and progress towards our near and long-term strategies. Patient Direct delivered mid-single digit top-line growth with strong performance in nearly all therapy categories led by Diabetes and Sleep Supplies. The top-line growth combined with strong operational execution delivered mid-teen e
Owens & Minor, Inc. (NYSE:OMI) plans to release financial results for the first quarter of 2025 on Thursday, May 8, 2025, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:00 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can b
Transformative investments in technology, automation and analytics capabilities will help improve supply chain visibility and resiliency for Products & Healthcare Services customers and lay the foundation for future innovations Owens & Minor, Inc. (NYSE:OMI) today announced important milestones in advancing the medical distribution capabilities of its Products & Healthcare Services (P&HS) business segment, which provides essential products and services to thousands of healthcare customers. These milestones are the result of recent company investments in new technology, automation and analytics capabilities geared specifically toward driving greater efficiencies for the P&HS segment and imp
Top-Line Growth Led by the Patient Direct Segment Patient Direct Operating Margin Expanded by 173 Basis Points Company Reaffirmed 2025 Financial Guidance Remain Actively Engaged in Potential Sale of Products & Healthcare Services Segment Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the first quarter ended March 31, 2025. "Across the business we continued to see strong execution and progress towards our near and long-term strategies. Patient Direct delivered mid-single digit top-line growth with strong performance in nearly all therapy categories led by Diabetes and Sleep Supplies. The top-line growth combined with strong operational execution delivered mid-teen e
Owens & Minor, Inc. (NYSE:OMI) plans to release financial results for the first quarter of 2025 on Thursday, May 8, 2025, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:00 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can b
Total Debt Reduction of $244 Million in 2024, Capping a Two-Year Total Debt Reduction of $647 Million 2025 Guidance Midpoint Indicates Double-Digit Adjusted EBITDA & Adjusted EPS Growth, and Improving Cash Flow Active Discussions Well Underway Regarding Potential Sale of Products & Healthcare Services (P&HS) Segment Board of Directors Authorizes Share Repurchase Program of Up to $100 Million Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the fourth quarter and year ended December 31, 2024. "We are pleased with the progress that we have made against the strategy as outlined at our Investor Day in December 2023. As a reminder, we committed to optimizing our Prod
SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)
SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)
SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)